Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $22.00 | Buy | Chardan Capital Markets |
| 7/18/2022 | $20.00 | Buy | H.C. Wainwright |
| 11/9/2021 | $30.00 → $23.00 | Overweight → Neutral | JP Morgan |
15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)
8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)
EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is retiring from Oyster Point's Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company. "On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years," said Jeffrey Nau, M.M.S, Ph.D., president and chief executive officer, Oy
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the appointment of a new Director and Chairperson to its Board of Directors. The Oyster Point Pharma Board of Directors is pleased to announce the appointment of Donald Santel as non-executive Chairperson and a Director of the Company and a member of the Compensation Committee. Don joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, M.D. steps down as Chairperson, remaining a
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the appointment of Marian Macsai, M.D., as Chief Medical Officer, and Eric Carlson, Ph.D., as Chief Scientific Officer, both of whom will join the executive leadership team, effective December 7, 2020. “I’m thrilled to welcome Drs. Macsai and Carlson to the executive leadership team at Oyster Point, as both will help expand and strengthen our organization during this time of unprecedented growth,” said
PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $11.20 per share, Oyster Point Pharma's
NEW YORK, NY / ACCESSWIRE / November 12, 2022 / Ritchie Bros. Auctioneers Incorporated (NYSE:RBA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common stock for each share of IAA common stock.If you are an RBA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Point Pharma, Inc. (NASDAQ:OYST)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connecti
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat
Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
Chardan Capital Markets initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $20.00
JP Morgan downgraded Oyster Point Pharma from Overweight to Neutral and set a new price target of $23.00 from $30.00 previously
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. (NASDAQ:VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmolo
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please register here to receive dial-in details or to select a call back. Webcast DetailsThe webcast will be made available on the compa
Six out of the 10 largest holdings in over 700 aggregated hedge fund portfolios are increasingly concentrated towards the ‘Magnificent Seven' stocks, with Tesla being the sole exception, according to the latest report by Goldman Sachs. What Happened: Insights from Goldman Sachs’ Hedge Fund Trend Monitor, an analysis led by Ben Snider, show an overzealous preference for just several mega-caps. This enthusiasm does not mirror their market weight. The Magnificent Seven accounts for a record 13% of the aggregate hedge fund long portfolios. Yet, it remains significantly underweighted compared to a 26% collective stake in the Russell 3000 — underscoring a cautious approach towards mega-cap
Oyster Point Pharma (NASDAQ:OYST) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.53) by 10.46 percent. This is a 101.47 percent decrease over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $5.59 million which missed the analyst consensus estimate of $6.93 million by 19.32 percent. This is a 68.84 percent decrease over sales of $17.94 million the same period last year.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. • Wix.com (NASDAQ:WIX) is expected to report quarterly loss at $0.09 per share on revenue of $343.33 million. • ArcelorMittal (NYSE:MT) is estimated to report quarterly earnings at $1.25 per share on revenue of $18.36 billion. • Navios Maritime Partners (NYSE:NMM) is estimated to report earnings for its third quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated to report earnings for its third quarter. • Dillard's (NYSE:DDS) is estimated to report earnings for its third quarter. • VerifyMe (NASDAQ:VRME) is projected to report earnings for its third quarter. • Wa